Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (309)	2/22/2003 10:26:41 PM
From: Jibacoa	Respond to of 3722

FLML The stock has remained on an UPTREND since November 19 and the price has had a good % run from the Ls last Summer. The earnings for the last Q were up to $0.14 and the PE is around 24 In December they received a$1.5M payment from GSK which is using their Micropump technology for long acting Augmentin. (FLML's Medusa nano-encapsulation technology is designed to deliver therapeutic proteins and its Micropump is a controlled release and taste-masking technology for the oral administration of small molecule drugs.) Their expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product which is been marketed by GLW. The chart doesn't look bad, but since I am getting rid of any French wines and cheese in my house, I decided to sell the small position I had on FLML as well.<g> siliconinvestor.com Bernard